Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bayer acquires Maxygen’s hemophilia program assets
The therapeutic candidate is expected to enter Phase I clinical testing in the third quarter of 2008. The total transaction is valued at $90 million upfront with a
The therapeutic candidate is expected to enter Phase I clinical testing in the third quarter of 2008. The total transaction is valued at $90 million upfront with a
Under the terms of the agreement, PainReform will obtain exclusive North American rights to ETI-211 and will also obtain an option to expand the agreement to other countries
Novartis disputes the State of Alabama’s claims that the prices provided by Novartis Pharmaceuticals (NPC) to reporting services resulted in overpayment to pharmacists and doctors in the Alabama
MiddleBrook has entered into a definitive securities purchase agreement with Equity Group Investments (EGI) for the sale of 30.30 million shares of its common stock at $3.30 per
The investment will allow Ibis to further develop the Ibis T5000 Biosensor System, which reportedly offers a unique solution for rapid identification and characterization of infectious agents. By
Dr LeBel has served on Akesis’s board of directors since December 2007. The company also stated that current president, Jay Lichter will retain the position of CEO and
Adam Singer, chairman and CEO of IPC, said: “The acquisition of Texas Inpatient Services (TIPS) continues to strengthen IPC’s position in this important market and sets the stage
Provista’s BT Test, a new blood test to aid healthcare providers in early breast cancer detection, will be provided through International Health Technology’s (IHT) women’s clinic for breast
The $2 million was structured as preferred shares which are convertible into common shares; the investor also received warrants in the deal. Midtown Partners & Co acted as
The study is designed to assess the bioavailability profile of increasing doses of PTH-1-34 combined with different amounts of 5-CNAC administered orally. The trial is being conducted in